ストックスクリーナーアプリを入手
1.36
0.74%
0.01
プレマーケット:
1.37
0.01
+0.74%
Ocugen Inc (OCGN) 最新ニュース
Why Did OCGN Stock Rise Today? - Stocktwits
Malvern’s Ocugen Starts Pivotal Trial for Eye Gene Therapy - MyChesCo
Ocugen stock edges higher as investors watch recent quarterly figures - AD HOC NEWS
Ocugen Stock Price Forecast. Should You Buy OCGN? - StockInvest.us
Ocugen Inc. stock rises Thursday, outperforms market - marketwatch.com
OCGN Advances Gene Therapy OCU410 In Phase III for Geographic Atrophy - Yahoo Finance
Ocugen Doses First Patient in Global Phase 3 Trial of OCU410 for Geographic Atrophy - eyewire.news
Ocugen Eases on Tests - Baystreet.ca
Ocugen doses first patient in phase 3 gene therapy trial for GA - Investing.com Canada
OCGN Looks 61.0% Overvalued on GF Value™ - GuruFocus
Ocugen Doses First Patient in Global Phase 3 ArMaDa3 Trial of OCU410 for Geographic Atrophy and Receives FDA RMAT Designation - Quiver Quantitative
Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration - ir.ocugen.com
Ocugen Doses First Patient in OCU410 Phase 3 Trial | OCGN Stock News - Stock Titan
Malvern Biotech Ocugen to Present New Eye Gene Therapy Data - MyChesCo
Ocugen Inc. stock falls Friday, underperforms market - marketwatch.com
Ocugen Inc. stock falls Thursday, underperforms market - marketwatch.com
Ocugen to Present Modifier Gene Therapy Platform at Upcoming Investor and Industry Conferences in September 2026 - Quiver Quantitative
Ocugen Inc. stock falls Monday, underperforms market - marketwatch.com
Ocugen's Q2 Earnings Miss Estimates as R&D Costs Rise, Stock Falls - Eastern Progress
Ocugen’s Earnings Call Highlights Risk-Reward Inflection - TipRanks
Ocugen (OCGN) Quarterly Results: Reported EPS Misses Expectations under the Current Snapshot; Share Response: Shares Move 10.45% Up at the CloseGuidance Update - Vinanet
Ocugen Inc. stock rises Wednesday, outperforms market - MarketWatch
Ocugen Inc (NASDAQ: OCGN) Stock Price, News & Analysis - Kalkine
Ocugen’s Phase 3 Gene Therapy Trial Targets High-Value Dry AMD Market - TipRanks
Fully funded pipeline in advanced stages. 30% short interest? for NASDAQ:OCGN by Ehrlichman - TradingView
Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch
symbol__ Stock Quote Price and Forecast - CNN
Ocugen Inc. stock rises Monday, outperforms market - MarketWatch
Ocugen (OCGN) Q2 2026 Earnings Call Transcript - AOL.com
Ocugen Targets 2027 BLA Filings as Gene Therapy Programs Near Key Readouts - marketbeat.com
Q2 2026 Ocugen Inc Earnings Call Transcript - GuruFocus
OCUGEN INC (OCGN) Stock Chart - ChartMill
Ocugen, Inc. (NASDAQ:OCGN) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Janus Henderson Group (OCGN) discloses 10M-share beneficial stake in Ocugen - Stock Titan
Ocugen Inc. stock rises Tuesday, outperforms market - MarketWatch
Ocugen at Canaccord Genuity’s 46th Annual Growth Conference: late-stage push - Investing.com Canada
Research Analysts Issue Forecasts for Ocugen Q3 Earnings - MarketBeat
What is Noble Financial's Forecast for Ocugen Q3 Earnings? - MarketBeat
Hennion & Walsh Asset Management Inc. Purchases 1,553,672 Shares of Ocugen, Inc. $OCGN - MarketBeat
Ocugen (NASDAQ:OCGN) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Ocugen Inc. stock rises Friday, outperforms market - MarketWatch
Ocugen Inc (OCGN) Stock News Today - TradingKey
0.86%
0.31%
大文字化:
|
ボリューム (24 時間):